Adjuvant Formulations Designed to Improve Swine Vaccine Stability: Application to PCV2 Vaccines

Arous, Juliette Ben; Boyer, François; Gaucheron, Jérôme; Verkhovsky, О.A.; Kotelnikov, A.P.; Shemelkov, E.V.; Alekseev, Konstantin P.; Dupuis, Laurent

doi:10.1016/j.provac.2013.06.007

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GEL is a new type of water-soluble polymer adjuvant, the main component of which is polyethylene acrylic acid sodium. The excellent effects of the GEL adjuvant have been verified in vaccines against several viruses, including an inactivated Porcine circovirus vaccine ( 44 ), an inactivated Porcine reproductive and respiratory syndrome virus vaccine ( 35 ), an inactivated equine influenza virus vaccine ( 45 ), a live attenuated porcine epidemic encephalitis vaccine ( 34 ), and a Bovine herpesvirus DNA vaccine ( 46 ). However, this adjuvant showed a poor adjuvant effect in an inactivated sheep paratuberculosis vaccine ( 30 ), a Rhodococcusequi subunit vaccine ( 47 ), and a bovine mite disease subunit vaccine ( 48 ).…”

Section: Discussionmentioning

confidence: 99%

“…The GEL adjuvant is a new polymer adjuvant that has been used in recent years. Recent studies have shown that it not only induces humoral immunity, but also significantly promotes T-lymphocyte proliferation and differentiation, resulting in high-level cellular immunity ( 34 , 44 ). Therefore, the two vaccines may cause different immune responses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae

et al. 2022

View full text Add to dashboard Cite

In this study, we screened adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae (E. rhusiopathiae). Inactivated cells of E. rhusiopathiae strain HG-1 were prepared as the antigen in five adjuvanted inactivated vaccines, including a mineral-oil-adjuvanted vaccine (Oli vaccine), aluminum-hydroxide-gel-adjuvanted vaccine (Alh vaccine), ISA201-biphasic-oil-emulsion-adjuvanted vaccine (ISA201 vaccine), GEL02-water-soluble-polymer-adjuvanted vaccine (GEL vaccine), and IMS1313-water-soluble-nanoparticle-adjuvanted vaccine (IMS1313 vaccine). The safety test results of subcutaneous inoculation in mice showed that Oli vaccine had the most severe side effects, with a combined score of 35, followed by the ISA201 vaccine (25 points), Alh vaccine (20 points), GEL vaccine (10 points), and IMS1313 vaccine (10 points). A dose of 1.5LD50 of strain HG-1 was used to challenge the mice intraperitoneally, 14 days after their second immunization. The protective efficacy of Oli vaccine and Alh vaccine was 100% (8/8), whereas that of the other three adjuvanted vaccines was 88% (7/8). Challenge with 2.5LD50 of strain HG-1 resulted in a 100% survival rate, demonstrating the 100% protective efficacy of the Oli vaccine, followed by the GEL vaccine (71%, 5/7), IMS1313 vaccine (57%, 4/7), ISA201 vaccine (43%, 3/7), and Alh vaccine (29%, 2/7). Challenge with 4LD50 of strain HG-1 showed 100% (7/7) protective efficacy of the Oli vaccine and 71% (5/7) protective efficacy of the GEL vaccine, whereas the protective efficacy of other three adjuvanted vaccine was 14% (1/7). The Alh and GEL vaccines were selected for comparative tests in piglets, and both caused minor side effects. A second immunization with these two adjuvanted vaccines conferred 60 and 100% protective efficacy, respectively, after the piglets were challenged via an ear vein with 8LD100 of strain HG-1. After challenge with 16LD100 of strain HG-1, the Alh and GEL vaccines showed 40% and 100% protective efficacy, respectively. Our results suggested that GEL is the optimal adjuvant for an inactivated vaccine against E. rhusiopathiae.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae

et al. 2022

View full text Add to dashboard Cite

show abstract

Enhanced Immune Responses Against Japanese Encephalitis Virus Infection Using Japanese Encephalitis Live-Attenuated Virus Adjuvanted with Montanide GEL 01 ST in Mice

Wang

Wei

et al. 2019

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

Adjuvants for Animal Vaccines

et al. 2018

View full text Add to dashboard Cite

Vaccines are essential tools for the prevention and control of infectious diseases in animals. One of the most important steps in vaccine development is the selection of a suitable adjuvant. The focus of this review is the adjuvants used in vaccines for animals. We will discuss current commercial adjuvants and experimental formulations with attention to mineral salts, emulsions, bacterial-derived components, saponins, and several other immunoactive compounds. In addition, we will also examine the mechanisms of action for different adjuvants, examples of adjuvant combinations in one vaccine formulation, and challenges in the research and development of veterinary vaccine adjuvants.

show abstract

Adjuvant Formulations Designed to Improve Swine Vaccine Stability: Application to PCV2 Vaccines

Cited by 3 publications

References 6 publications

Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae

Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae

Enhanced Immune Responses Against Japanese Encephalitis Virus Infection Using Japanese Encephalitis Live-Attenuated Virus Adjuvanted with Montanide GEL 01 ST in Mice

Adjuvants for Animal Vaccines

Contact Info

Product

Resources

About